Skip to content
MARKETS / NASDAQ / YARW
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Yarrow Bioscience, Inc. YARW

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$570,000
▲ 13.8% YoY
$-26.5M
$-33.1M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth
USD 570,000.00
Revenue, FY2025 · full 11-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.6 · Net income -26.5
-100M-200M201520172019202120232025
Compound annual growth
+6.1%
−51.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −51.4% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
·
Operating margin Net margin
FY2025 · Operating -5219.1% · Net ·
-10000%-20000%201520172019202120232025
ROE
FY2025 · ROE -66.3%
-500%201520172019202120232025
Three returns, three denominators.

Each USD of equity lost 66 cents this year.

Cash & shareholders
·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -33.1
-50M-100M201520172019202120232025

Total assetsUSD 30.2M
EquityUSD 27.8M
CashUSD 24.0M
Gross debtUSD 0.00
Net debtUSD -24.0M
Current ratio12.53×

The company holds more cash than debt.

The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015
Revenue $B0.00.00.00.00.00.00.00.00.00.0·
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.3−0.1−0.1−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.3−0.1−0.1···
Income tax $B0.00.00.00.0−0.0−0.0−0.00.00.0··
Net income $B−0.0−0.0−0.0−0.0−0.1−0.3−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0·−0.1−0.1−0.1−0.1−0.0−0.0−0.0
EPS, diluted $−0.62−0.93−2.78−7.28−25.64−7.8811.2211.47−5.69−2.82−0.97
Dividend / sh $···········
Payout %···········
ROE %−66.3−56.6−47.4−58.1−170.3−928.2−173.4−92.3−148.5··
Shares out B0.030.010.010.000.000.040.010.020.010.01·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 42 reconciliationsAUDITED

Reconciled in 11 of 19 fiscal years. 18 checks were skipped: the balance sheet is not tagged before 2016. 11 checks were skipped: cost of revenue is not tagged before 2018. Eight checks were skipped: EPS is not tagged before 2015.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2015

Share this section

Download image